FDA approves Medtronic's Evolut FX+ TAVR system for severe aortic stenosis. Enhanced coronary access, maneuverability for diverse anatomies. Early Commercial Experience in spring 2024.
Medtronic s PulseSelect Pulsed Field Ablation System has become the first to receive FDA approval for the treatment of both paroxysmal and persistent atrial fib
Medtronic said the U.S. Food and Drug Administration has approved its PulseSelect Pulsed Field Ablation System for the treatment of two heart conditions.